{"changes":[{"companyHref":"/c/calderatx-com","date":"2026-09-25","documentUrl":"https://www.sec.gov/Archives/edgar/data/2069936/000206993626000001/primary_doc.xml","domain":"calderatx.com","fact":"latest round","name":"Caldera Therapeutics, Inc.","new":{"amountUsd":37500000,"date":"2026-01-08","lead":null,"type":null},"old":{"amountUsd":37500000,"date":"2026-01-08","lead":null,"type":"seed"},"publisher":"SEC EDGAR","reason":null,"retrievedAt":"2026-09-25","slug":"calderatx-com","status":"sourced","url":"https://whoraisedwhat.com/c/calderatx-com"},{"companyHref":"/c/calderatx-com","date":"2026-09-25","documentUrl":"https://www.sec.gov/Archives/edgar/data/2069936/000206993626000001/primary_doc.xml","domain":"calderatx.com","fact":"provenance:round","name":"Caldera Therapeutics, Inc.","new":{"publisher":"SEC EDGAR","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/2069936/000206993626000001/primary_doc.xml"},"old":{"publisher":"sec-edgar","status":"attributed","url":null},"publisher":"SEC EDGAR","reason":null,"retrievedAt":"2026-09-25","slug":"calderatx-com","status":"sourced","url":"https://whoraisedwhat.com/c/calderatx-com"}],"country":"US","description":"Caldera Therapeutics is a clinical-stage biotech developing the first-in-class bispecific antibody CLD-423 for inflammatory bowel disease and other inflammatory conditions. It targets patients and clinicians facing IBD that has plateaued on single-target therapies. Its differentiator is hitting two validated pathways, IL-23p19 and TL1A, in one molecule.","domain":"calderatx.com","employees":null,"founded":2025,"fundingTotalQuarantined":false,"githubOrg":"calderatx","githubStars":null,"industry":"biotechnology","investors":[],"lat":42.365635,"lng":-71.104002,"location":"Cambridge, Massachusetts","name":"Caldera Therapeutics, Inc.","rounds":[{"amountQuarantined":false,"amountUsd":37500000,"currency":"USD","date":"2026-01-08","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"SEC EDGAR","retrievedAt":"2026-09-25","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/2069936/000206993626000001/primary_doc.xml"},"status":"sourced","type":null,"url":"https://www.sec.gov/Archives/edgar/data/2069936/000206993626000001/primary_doc.xml"}],"slug":"calderatx-com","sources":[{"fact":"round","publisher":"SEC EDGAR","retrievedAt":"2026-09-25","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/2069936/000206993626000001/primary_doc.xml"},{"fact":"existence","publisher":"calderatx.com","retrievedAt":"2026-05-06","status":"self-reported","url":"https://calderatx.com"},{"fact":"description","publisher":"calderatx.com","retrievedAt":"2026-05-06","status":"self-reported","url":"https://calderatx.com"}],"stage":null,"techStack":["Typekit","Adobe Fonts","Afterpay","Sentry","Spin.js","Squarespace","Squarespace Commerce","Stimulus","parallax.js","web-vitals","moment 0","@sentry/browser"],"totalRaisedUsd":37500000,"updatedAt":"2026-05-06"}